Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.

ABSTRACT:

Background

Prostate cancer exhibits biological and clinical heterogeneity even within established clinico-pathologic risk groups. The Decipher genomic classifier (GC) is a validated method to further risk-stratify disease in patients with prostate cancer, but its performance solely within National Comprehensive Cancer Network (NCCN) high-risk disease has not been undertaken to date.

Methods

A multi-institutional retrospective study of 405 men with high-risk prostate cancer who underwent primary treatment with radical prostatectomy (RP) or radiation therapy (RT) with androgen-deprivation therapy (ADT) at 11 centers from 1995 to 2005 was performed. Cox proportional hazards models were used to determine the hazard ratios (HR) for the development of metastatic disease based on

SUBMITTER: Tosoian JJ 

PROVIDER: S-EPMC10184170 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature